4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MaxCyte, Inc. (MXCT) operates in the Medical Devices industry and is headquartered in Rockville, United States with about 91 employees. Its market capitalization is roughly $164 million. In the fiscal year ended 2025-12-31, MXCT reported $33M in revenue and ($45M) in net income.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Interactive charts & full statements → Open the MXCT valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $31M | $33M | $39M | $41M | $44M | — |
| Gross Profit | $25M | $27M | $32M | $36M | $39M | — |
| Operating Income (EBIT) | ($42M) | ($52M) | ($51M) | ($48M) | ($27M) | — |
| Net Income | ($36M) | ($45M) | ($41M) | ($38M) | ($24M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|---|
| Total Revenue | $7M | $10M | $7M | $7M | $8M |
| Gross Profit | $6M | $8M | $6M | $5M | $7M |
| Operating Income (EBIT) | ($10M) | ($6M) | ($11M) | ($14M) | ($14M) |
| Net Income | ($9M) | ($5M) | ($10M) | ($12M) | ($12M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $202M | $240M | $268M | $287M | — |
| Total Liabilities | $31M | $33M | $36M | $33M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MXCT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms